Ankur Mehta, Joint Managing Director and Promoter of corona remedies , has declared that no encumbrance has been made on the equity shares held by him or Persons Acting in Concert (PACs) during the financial year 2025-2026. The disclosure, submitted to the stock exchanges, confirms that neither the promoter nor the identified PACs have encumbered any equity shares of the company, whether held directly or indirectly, throughout the specified financial period. This filing was made under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The declaration was addressed to the Department of Corporate Relations at BSE Limited and the Department of Corporate Services at the National Stock Exchange of India Limited. A copy was also forwarded to the Audit Committee and the Company Secretary and Compliance Officer of CORONA Remedies Limited for their records.

Persons Acting in Concert

The disclosure includes an annexure listing the individuals and entities classified as PACs, categorized under Promoter and Promoter Group. The list comprises family members and associated entities of the promoter.

CORONA Remedies has announced a final dividend of ₹10 per equity share for the financial year 2025-26. The Board of Directors recommended the dividend at a meeting held on May 11, 2026. This payout is subject to approval by shareholders at the ensuing 22nd Annual General Meeting.

The dividend will be paid to shareholders whose names appear in the Register of Members or Register of Beneficial Owners as on Friday, June 19, 2026. The company stated that bank particulars registered with Depository Participants would be used for the payment. Shareholders have been requested to update their address, bank mandate, PAN, and KYC details with their Depository Participants before the record date to ensure timely credit.

Tax Deduction at Source

The company informed shareholders that it is required to withhold tax on dividends in accordance with the Income Tax Act, 2025. The applicable tax rate varies based on the residential status of the shareholder and the documents submitted. Shareholders must update or verify their PAN, address, email, and residential status with their Depository Participants. The company will rely on details available with the Registrar to Issue and Share Transfer Agent, Bigshare Services Private Limited.

TDS Rates for Resident Shareholders

The communication outlined specific Tax Deducted at Source (TDS) rates for different categories of resident shareholders. The table below details the applicable rates and conditions.

TDS Rates for Non-Resident Shareholders

For non-resident shareholders, tax will be deducted at 20% plus applicable surcharge and cess, or the tax treaty rate, whichever is beneficial. Specific documents, such as a Tax Residency Certificate and digital Form 41, are mandatory to avail of the beneficial treaty rate. Sovereign Wealth funds and Pension funds notified by the Central Government are eligible for a NIL TDS rate upon submission of necessary declarations.

Shareholders are required to submit relevant documents, including Form 121 and self-declarations, to the company's Registrar via email at tds@bigshareonline.com on or before June 19, 2026. Any communication received after this date will not be considered for tax rate determination.